Navigation Links
Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
Date:12/19/2011

REDMOND, Wash., Dec. 19, 2011 /PRNewswire/ -- Cerevast Therapeutics Inc., a privately held medical technology company, announced today that it has received CE mark clearance of its SonoLysis Headframe System, the Clotbust ER™ providing approval to commercialize the product in Europe.

(Logo: http://photos.prnewswire.com/prnh/20111219/SF24705LOGO)

The Clotbust ER™ is a first-in-class ultrasound device for the treatment of ischemic stroke, representing a novel product in an extremely high area of unmet medical need. Designed for rapid deployment in the emergency room setting, the device has been engineered to non-invasively deliver therapeutic ultrasound energy to the region of the occluded vessel in the brain as a treatment for ischemic stroke when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase).

The device contains multiple transducers incorporated into a unique, operator-independent headframe.  The Clotbust ER™ is designed to self-align the transducers based on common landmarks on the skull.  Proprietary software controls the ultrasound parameters, which in turn allows the device to deliver consistent therapeutic levels of ultrasound energy necessary to achieve acoustic streaming and enhanced clot lysis within the occluded vessel of the brain without the need for a trained sonographer or vascular technician.

"Achieving CE mark clearance represents a major accomplishment for Cerevast," said Bradford A. Zakes, Chief Executive Officer. "The Clotbust ER™ significantly reduces the technical challenges associated with the administration of transcranial ultrasound for the treatment of ischemic stroke.  Unlike conventional Doppler instruments that are designed and approved for diagnostic purposes only, the Clotbust ER™ delivers therapeutic ultrasound energy to the region of the occlusion without the need to aim the transducer or hold it in place by hand for extended periods of time.  This represents a major advancement in the emergency room setting where trained sonographers or vascular technicians are not always available."

"It is critically important that treatment be initiated as quickly as possible once a stroke patient presents to the hospital," said Andrei Alexandrov, MD, Professor of Neurology and Director, UAB Comprehensive Stroke Research Center.  "The operator-independent design of the Clotbust ER™ enables safe, fast and reliable amplification of systemic thrombolytic treatment in the emergency room setting.  I look forward to the benefit this product will bring to those patients that suffer the debilitating effects of an ischemic stroke."

About Cerevast Therapeutics, Inc.

Cerevast Therapeutics, Inc. is a medical technology company focused on the development of SonoLysis for the treatment of acute ischemic stroke. Cerevast is a recognized leader in the field of SonoLysis with a dominant intellectual property estate comprising more than 75 issued U.S. patents, 250 foreign issued equivalents and an extensive data package of pre-clinical and clinical studies. The Company is a privately held corporation headquartered in Redmond, WA.

About SonoLysis

SonoLysis is the term used to describe the application of ultrasound energy to disrupt or "lyse" blood clots in the vasculature.  In the setting of acute ischemic stroke, clinical studies have demonstrated that the combination of transcranial ultrasound with conventional thrombolytic therapy results in a significant improvement in both vessel recanalization and rate of complete recovery compared to conventional thrombolytic therapy alone – a major advance in treatment.

 


'/>"/>
SOURCE Cerevast Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):